Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-08-15

Clinical Trial Update: A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels

View source ↗

Summary

This update reports quality-of-life results from a study of peginterferon alfa-2a plus ribavirin in participants with chronic hepatitis C and persistently norma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Copegus (ribavirin)
  • Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Status: COMPLETED | Results posted: 2016-08-15